Stock 0QJU DOTTIKON ES HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dottikon ES Holding AG CINNOBER BOAT

Equities

0QJU

CH0020739006

Pharmaceuticals

Delayed CINNOBER BOAT
Other stock markets
 		5-day change 1st Jan Change
- CHF -.--% Intraday chart for Dottikon ES Holding AG -.--% -.--%
2023 Dottikon ES Posts Lower Fiscal H1 Net Income; Sales Up MT
2023 Dottikon ES Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023 CI

Valuation

Fiscal Period: March 2019 2021 2022 2023 2024 2025 2026
Capitalization 1 556.3 2,522 3,500 3,583 3,548 - -
Enterprise Value (EV) 1 556.3 2,337 3,500 3,424 3,548 3,548 3,548
P/E ratio 34.2 x - 59.2 x 40.9 x 36 x 35.3 x -
Yield - - - - - - -
Capitalization / Revenue - 11.5 x 13.9 x 11.2 x 10.8 x - -
EV / Revenue - 11.5 x 13.9 x 11.2 x 10.8 x - -
EV / EBITDA - 31.6 x 39.4 x 30.7 x 29.2 x - -
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - 3.52 x - 4.47 x - - -
Nbr of stocks (in thousands) 12,502 13,780 13,780 13,780 13,780 - -
Reference price 2 44.50 183.0 254.0 260.0 257.5 257.5 257.5
Announcement Date 28/05/19 28/05/21 31/05/22 31/05/23 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2021 2022 2023 2024 2025 2026
Net sales 1 - 218.9 251.9 319.5 330 - -
EBITDA 1 - 79.78 88.79 116.6 121.4 - -
EBIT 1 - 60.64 67.66 96 100.3 - -
Operating Margin - 27.7% 26.86% 30.05% 30.39% - -
Earnings before Tax (EBT) - - - - - - -
Net income 1 16.26 - 59.3 - 85.7 - -
Net margin - - 23.54% - 25.97% - -
EPS 2 1.300 - 4.290 6.350 7.160 7.300 -
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 28/05/19 28/05/21 31/05/22 31/05/23 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 S1 2023 S1 2024 S1
Net sales 1 - 133.8 152.6
EBITDA 1 - 47.1 52.62
EBIT 1 - 37.5 42.57
Operating Margin - 28.03% 27.91%
Earnings before Tax (EBT) - - -
Net income 1 23.92 38.9 37.38
Net margin - 29.07% 24.5%
EPS - - -
Dividend per Share - - -
Announcement Date 26/11/21 29/11/22 28/11/23
1CHF in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - 185 - 159 - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - 9.89% - 11.6% - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - 52.00 - 58.10 - - -
Cash Flow per Share 2 - 4.760 2.620 6.480 8.150 8.120 8.800
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 28/05/19 28/05/21 31/05/22 31/05/23 - - -
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
257.5
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.36% 709B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.77% 595B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.60% 367B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.07% 334B
ABBVIE INC. Stock AbbVie Inc.
+6.04% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.77% 239B
NOVARTIS AG Stock Novartis AG
+9.13% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-3.97% 203B
AMGEN INC. Stock Amgen Inc.
+9.27% 171B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DESN Stock
  4. 0QJU Stock
  5. Financials Dottikon ES Holding AG